60
Zhejiang Hisun
600267.SS·SSETaizhou CNFounded 19568,000 employees
Mid CappharmaPublicOncologyInfectious Disease
Platform: API Formulation
Market Cap
$2B
All Drugs
2
Clinical Trials
5
Failed / Terminated
2
FDA Approved
0
Stock Price & Catalysts (600267.SS)
Loading 600267.SS stock data...
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| 600-3422 | 600-3422 | Phase 1 | 2 | KRASG12D | ADHDProstate Ca | ||
| Bemasertib | 600-3865 | Phase 3 | 3 | Nectin-4 | Heart Failure |
SEC Filings & Financial Documents
SEC filings are not available for SSE-listed companies.
Zhejiang Hisun trades on SSE (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (5)